Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMG3F94)

Drug Name
Mestranol Drug Info
Synonyms
Devocin; Menophase; Mestranolo; Mestranolum; Norquen; Ovastol; Component of Norinyl; Component of Norquen; Component of Ovulen; Ethynylestradiol methyl ether; Mestranol [Steroidal oestrogens]; Mestranolo [DCIT]; EE3ME; Ethinyl Estradiol 3 Methyl Ether; SC 4725; Component of Ortho-Novum; Delta-MVE; EE(sub3)ME; EthinylEstradiol 3-Methyl Ether; Ethinylestradiol 3-methyl ether; Ethinyloestradiol 3-methyl ether; Ethynylestradiol 3-methyl ether; Ethynyloestradiol 3-methyl ether; Inostral (steroid); Mestranolum [INN-Latin]; Mestranol (JP15/USP/INN); Mestranol [USAN:INN:BAN:JAN]; Alpha.-19-Norpregna-1,3,5(10)-trien-20-yn-17-ol, 3-meth; (17beta)-17-ethynyl-3-(methyloxy)estra-1,3,5(10)-trien-17-ol; 17-Ethynyl-3-methoxy-1,3,5(10)-oestratien-17-beta-ol; 17-Ethynyl-3-methoxyestra-1,3,5(10)-trien-17-ol; 17-Ethynylestradiol 3-methyl ether; 17-Ethynyloestradiol 3-methyl ether; 17-alpha-Ethinyl estradiol 3-methyl ether; 17-alpha-Ethinyl oestradiol 3-methyl ether; 17-alpha-Ethynyl-3-methoxy-1,3,5(10)-estratrien-17-beta-ol; 17-alpha-Ethynyloestradiol methyl ether; 17-ethynyl-3-methoxyestra-1(10),2,4-trien-17beta-ol; 17-ethynyl-3-methoxyoestra-1(10),2,4-trien-17beta-ol; 17alpha-Ethinyl estradiol 3-methyl ether; 17alpha-Ethinyl oestradiol 3-methyl ether; 17alpha-Ethinylestradiol 3-methyl ether; 17alpha-Ethynylestradiol 3-methyl ether; 17alpha-Ethynylestradiol methyl ether; 17alpha-Ethynyloestradiol 3-methyl ether; 17beta-Estradiol, 17-ethynyl-, 3-(methyl ether); 3-Methoxy-17-alpha-19-norpregna-1,3,5(10)-trien-20-yn-17-ol; 3-Methoxy-17-alpha-ethinylestradiol; 3-Methoxy-17-alpha-ethinyloestradiol; 3-Methoxy-17-alpha-ethynyl-1,3,5(10)-estratrien-17-beta-ol; 3-Methoxy-17-alpha-ethynyl-1,3,5(10)-oestratrien-17-beta-ol; 3-Methoxy-17-alpha-ethynylestradiol; 3-Methoxy-17-alpha-ethynyloestradiol; 3-Methoxy-17-ethynyloestradiol-17-beta; 3-Methoxy-17alpha-ethinylestradiol; 3-Methoxy-17alpha-ethinyloestradiol; 3-Methoxy-17alpha-ethynyl-1,3,5(10)-estratrien-17beta-ol; 3-Methoxy-17alpha-ethynyl-1,3,5(10)-oestratrien-17beta-ol; 3-Methoxy-17alpha-ethynylestradiol; 3-Methoxy-17alpha-ethynyloestradiol; 3-Methoxy-19-nor-17-alpha-pregna-1,3,5(10)-trien-20-yn-17-ol; 3-Methoxy-19-nor-17alpha-pregna-1,3,5(10)-trien-20-yn-17-ol; 3-Methoxy-19-norpregna-1,3,5(10)-trien-20-yn-17beta-ol; 3-Methoxyethynylestradiol; 3-Methoxyethynyloestradiol; 3-Methylethynylestradiol; 3-Methylethynyloestradiol; 3-O-Methylethynylestradiol
Therapeutic ClassEstrogens
Cross-matching ID
PubChem CID
6291
ChEBI ID
CHEMBL6784
CAS Number
CAS 72-33-3
TTD Drug ID
D0J1ML
INTEDE Drug ID
DR1034

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
DNA replication 2.05 5.41e-3 34/36 (94.44%) MCM5;FEN1;MCM7;...
Cell cycle 2.01 2.71e-3 110/124 (88.71%) CDC20;CDC25B;CCNA2;...
Spliceosome 1.92 5.41e-3 101/150 (67.33%) PRPF4;SNRPD1;PUF60;...
Ribosome biogenesis in eukaryotes 1.85 8.12e-3 52/108 (48.15%) XPO1;NOP56;NAT10;...
Fanconi anemia pathway 1.84 7.58e-3 36/54 (66.67%) CENPX;USP1;RMI1;...
RNA transport 1.81 7.22e-3 128/186 (68.82%) XPO1;EIF5;NUP62;...
Cysteine and methionine metabolism 1.72 2.09e-2 43/50 (86%) ADI1;MAT2A;AMD1;...
Base excision repair 1.69 2.84e-2 29/33 (87.88%) FEN1;POLE2;HMGB1;...
Apoptosis -1.74 1.80e-2 126/168 (75%) EIF2S1;NFKB1;PMAIP1;...
Non-alcoholic fatty liver disease -1.74 1.86e-2 126/155 (81.29%) NDUFB7;INS;PRKAG2;...
Salmonella infection -1.76 1.67e-2 198/249 (79.52%) CDC42;PIK3C3;TLR6;...
Graft-versus-host disease -1.77 1.63e-2 32/42 (76.19%) HLA-DOB;HLA-G;TNF;...
Shigellosis -1.77 1.64e-2 180/246 (73.17%) TNF;FOXO4;NLRP3;...
Fluid shear stress and atherosclerosis -1.77 1.70e-2 123/139 (88.49%) TNF;CALML5;CTSL;...
PPAR signaling pathway -1.78 1.65e-2 66/74 (89.19%) PPARG;HMGCS1;FADS2;...
ECM-receptor interaction -1.78 1.73e-2 80/88 (90.91%) THBS3;ITGB5;ITGA7;...
Lipid and atherosclerosis -1.79 1.74e-2 190/215 (88.37%) AGER;CDC42;CAMK2A;...
Mitophagy -1.80 1.21e-2 56/68 (82.35%) BCL2L13;TFE3;TBC1D15;...
Proteoglycans in cancer -1.81 1.28e-2 172/205 (83.9%) MAPK1;GAB1;TWIST1;...
Other glycan degradation -1.81 1.34e-2 13/18 (72.22%) MAN2C1;AGA;GLB1;...
Glycosaminoglycan degradation -1.81 1.42e-2 19/19 (100%) GLB1;HYAL1;IDUA;...
Toll-like receptor signaling pathway -1.82 1.42e-2 94/104 (90.38%) IFNB1;RIPK1;MAPK14;...
C-type lectin receptor signaling pathway -1.82 1.24e-2 93/104 (89.42%) NFKB1;IL23A;PIK3CA;...
IL-17 signaling pathway -1.85 7.56e-3 84/94 (89.36%) CASP8;JUN;LCN2;...
Oxidative phosphorylation -1.86 6.07e-3 93/133 (69.92%) NDUFB11;NDUFB4;NDUFB1;...
NOD-like receptor signaling pathway -1.88 6.54e-3 145/181 (80.11%) IFNB1;RIPK1;MAPK14;...
Tuberculosis -1.89 7.09e-3 159/180 (88.33%) JAK1;PIK3C3;CAMK2A;...
alpha-Linolenic acid metabolism -1.91 6.44e-3 17/25 (68%) PLA2G10;PLA2G1B;FADS2;...
Leishmaniasis -1.97 4.25e-3 67/77 (87.01%) JAK1;NFKB1;FOS;...
Bladder cancer -1.97 4.72e-3 40/41 (97.56%) RPS6KA5;MAP2K1;ERBB2;...
Vibrio cholerae infection -2.00 3.54e-3 44/50 (88%) SLC12A2;ATP6V1F;TJP2;...
Malaria -2.01 4.05e-3 44/50 (88%) TNF;IL1B;THBS3;...
Epithelial cell signaling in Helicobacter pylori infect... -2.02 4.72e-3 62/70 (88.57%) CDC42;NFKB1;NOD1;...
Rheumatoid arthritis -2.04 2.83e-3 78/93 (83.87%) IL23A;FOS;HLA-DOB;...
Lysosome -2.09 0.00e+0 115/128 (89.84%) AP3M2;DNASE2;AGA;...
Collecting duct acid secretion -2.13 0.00e+0 22/27 (81.48%) ATP6V0C;ATP6V1B2;ATP6V1C1;...
Legionellosis -2.25 0.00e+0 51/57 (89.47%) BCL2L13;CXCL3;CR1;...
Phagosome -2.39 0.00e+0 118/152 (77.63%) C1R;TUBB1;HLA-DOB;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 0.12uM - 10uM 6H, 24H, 48H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H, 48H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 6H, 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 6H, 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 6H, 24H, 48H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 10uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 6H, 24H